PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, a Phase 3-ready therapeutic candidate with the potential to establish a new standard of care (SOC) for the treatment of idiopathic…more
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, a Phase 3-ready therapeutic candidate with the potential to establish a new standard of care (SOC) for the treatment of idiopathic…more
Latest RNS from PureTech Health plc
- holdingsHolding(s) in Company
- interim_resultsHalf-year Report
- product_launchPRTC Launches Celea w/ $180M & Top Tier Syndicate
- product_launchPRTC Launches Celea: $180M & Asset Transfer
Analyst consensus: Buy
As of 6 Oct 2026, 4 analysts rate PureTech Health plc a Buy, with 100% buy ratings and a mean price target of 370p (range 248p–509p), +231% vs the current price.